CN1293669A - 苄基哌嗪基-和苄基哌啶基-乙酮衍生物、其制备方法及其用作多巴胺d 受体拮抗剂的用途 - Google Patents
苄基哌嗪基-和苄基哌啶基-乙酮衍生物、其制备方法及其用作多巴胺d 受体拮抗剂的用途 Download PDFInfo
- Publication number
- CN1293669A CN1293669A CN99804026A CN99804026A CN1293669A CN 1293669 A CN1293669 A CN 1293669A CN 99804026 A CN99804026 A CN 99804026A CN 99804026 A CN99804026 A CN 99804026A CN 1293669 A CN1293669 A CN 1293669A
- Authority
- CN
- China
- Prior art keywords
- compound according
- hydrogen
- piperazinyl
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical class CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 title claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title description 10
- 238000002360 preparation method Methods 0.000 title description 9
- 229960003638 dopamine Drugs 0.000 title description 5
- 239000002464 receptor antagonist Substances 0.000 title description 2
- 229940044551 receptor antagonist Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 164
- 239000001257 hydrogen Substances 0.000 claims abstract description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 86
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 66
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 33
- 239000001301 oxygen Substances 0.000 claims abstract description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 29
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 28
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 27
- 150000002367 halogens Chemical group 0.000 claims abstract description 27
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 125000004429 atom Chemical group 0.000 claims abstract description 14
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000011593 sulfur Substances 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
- -1 1- (2-methyldihydroindolyl) -2- (4- (4-methylbenzyl) piperazinyl) ethan-1-one Chemical compound 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 125000006413 ring segment Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- PFPMRAONSOVYMJ-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)ethanone Chemical compound C1=CC(Cl)=CC=C1CN1CCN(CC(=O)N2C3=CC=CC=C3CCC2)CC1 PFPMRAONSOVYMJ-UHFFFAOYSA-N 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- OTFXBGZPWISICK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-1-(2,3-dihydro-1,4-benzothiazin-4-yl)ethanone Chemical compound C1=CC(Cl)=CC=C1CN1CCN(CC(=O)N2C3=CC=CC=C3SCC2)CC1 OTFXBGZPWISICK-UHFFFAOYSA-N 0.000 claims description 3
- UHEJJZNLPMHGJA-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-1-(2,3-dihydroindol-1-yl)ethanone Chemical compound C1=CC(Cl)=CC=C1CN1CCN(CC(=O)N2C3=CC=CC=C3CC2)CC1 UHEJJZNLPMHGJA-UHFFFAOYSA-N 0.000 claims description 3
- JIFUZIJTCAAWNY-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-1-(2-methyl-2,3-dihydroindol-1-yl)ethanone Chemical compound CC1CC2=CC=CC=C2N1C(=O)CN(CC1)CCN1CC1=CC=C(Cl)C=C1 JIFUZIJTCAAWNY-UHFFFAOYSA-N 0.000 claims description 3
- GFOKGPPIAVDUEO-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-1-(2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound C1=CC(Cl)=CC=C1CN1CCN(CC(=O)N2C3=CC=CC=C3OCC2)CC1 GFOKGPPIAVDUEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- BTPNUSAMOPUWIV-UHFFFAOYSA-N n-butyl-2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(CCCC)C(=O)CN(CC1)CCN1CC1=CC=C(Cl)C=C1 BTPNUSAMOPUWIV-UHFFFAOYSA-N 0.000 claims description 2
- SOQFNQVDTQYLAU-UHFFFAOYSA-N 1-(2,2-dimethyl-3h-indol-1-yl)-2-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]ethanone Chemical compound CC1(C)CC2=CC=CC=C2N1C(=O)CN(CC1)CCN1CC1=CC=C(F)C=C1 SOQFNQVDTQYLAU-UHFFFAOYSA-N 0.000 claims 1
- KHVLJSINWHWOLW-UHFFFAOYSA-N 1-(2,2-dimethyl-3h-indol-1-yl)-2-[4-[(4-methylphenyl)methyl]piperazin-1-yl]ethanone Chemical compound C1=CC(C)=CC=C1CN1CCN(CC(=O)N2C(CC3=CC=CC=C32)(C)C)CC1 KHVLJSINWHWOLW-UHFFFAOYSA-N 0.000 claims 1
- DMXHVLSOYPCZTE-UHFFFAOYSA-N 1-(2,3-dihydroindol-1-yl)-2-[4-[(4-methylphenyl)methyl]piperazin-1-yl]propan-1-one Chemical compound C1CC2=CC=CC=C2N1C(=O)C(C)N(CC1)CCN1CC1=CC=C(C)C=C1 DMXHVLSOYPCZTE-UHFFFAOYSA-N 0.000 claims 1
- JZOCWMYEGAHLAF-UHFFFAOYSA-N 1-(5-chloro-2,2-dimethyl-3h-indol-1-yl)-2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]ethanone Chemical compound CC1(C)CC2=CC(Cl)=CC=C2N1C(=O)CN(CC1)CCN1CC1=CC=C(Cl)C=C1 JZOCWMYEGAHLAF-UHFFFAOYSA-N 0.000 claims 1
- YWWSNUCDECZHPM-UHFFFAOYSA-N 1-(6-chloro-2,3-dihydroindol-1-yl)-2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]ethanone Chemical compound C1=CC(Cl)=CC=C1CN1CCN(CC(=O)N2C3=CC(Cl)=CC=C3CC2)CC1 YWWSNUCDECZHPM-UHFFFAOYSA-N 0.000 claims 1
- MRQPAQHCUBEBQD-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-1-(2,2-dimethyl-3h-indol-1-yl)ethanone Chemical compound CC1(C)CC2=CC=CC=C2N1C(=O)CN(CC1)CCN1CC1=CC=C(Cl)C=C1 MRQPAQHCUBEBQD-UHFFFAOYSA-N 0.000 claims 1
- XAJRENDYYQHIBY-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-1-(4-fluoro-2,3-dihydroindol-1-yl)ethanone Chemical compound C1CC=2C(F)=CC=CC=2N1C(=O)CN(CC1)CCN1CC1=CC=C(Cl)C=C1 XAJRENDYYQHIBY-UHFFFAOYSA-N 0.000 claims 1
- COJAZIUIZFFLJD-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-1-(7-methyl-2,3-dihydroindol-1-yl)ethanone Chemical compound C1=2C(C)=CC=CC=2CCN1C(=O)CN(CC1)CCN1CC1=CC=C(Cl)C=C1 COJAZIUIZFFLJD-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 239000000543 intermediate Substances 0.000 abstract description 8
- 125000003545 alkoxy group Chemical group 0.000 abstract description 7
- 201000000980 schizophrenia Diseases 0.000 abstract description 6
- 239000003176 neuroleptic agent Substances 0.000 abstract description 4
- 230000003557 neuropsychological effect Effects 0.000 abstract description 4
- 206010026749 Mania Diseases 0.000 abstract description 3
- 201000009032 substance abuse Diseases 0.000 abstract description 3
- 231100000736 substance abuse Toxicity 0.000 abstract description 3
- 208000011117 substance-related disease Diseases 0.000 abstract description 3
- 208000019901 Anxiety disease Diseases 0.000 abstract description 2
- 206010012289 Dementia Diseases 0.000 abstract description 2
- 230000036506 anxiety Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000019430 Motor disease Diseases 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 150000002366 halogen compounds Chemical class 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000015554 Dopamine receptor Human genes 0.000 description 5
- 108050004812 Dopamine receptor Proteins 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- GOYAXTCAJAVGBK-UHFFFAOYSA-N 2-(4-benzylpiperazin-1-yl)acetaldehyde Chemical class C1CN(CC=O)CCN1CC1=CC=CC=C1 GOYAXTCAJAVGBK-UHFFFAOYSA-N 0.000 description 3
- ARHQTTKUMFDVJJ-UHFFFAOYSA-N 2-chloro-1-(2,3-dihydroindol-1-yl)ethanone Chemical compound C1=CC=C2N(C(=O)CCl)CCC2=C1 ARHQTTKUMFDVJJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- KRVOJOCLBAAKSJ-RDTXWAMCSA-N (2R,3R)-nemonapride Chemical compound C1=C(Cl)C(NC)=CC(OC)=C1C(=O)N[C@H]1[C@@H](C)N(CC=2C=CC=CC=2)CC1 KRVOJOCLBAAKSJ-RDTXWAMCSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FQBQQQUTIFHUTE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9-heptadecaethoxyhexadecan-1-ol Chemical compound C(C)OC(C(C(C(C(C(C(C(C(O)(OCC)OCC)(OCC)OCC)(OCC)OCC)(OCC)OCC)(OCC)OCC)(OCC)OCC)(OCC)OCC)(OCC)OCC)CCCCCCC FQBQQQUTIFHUTE-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- GSJXJZOWHSTWOX-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]piperazine Chemical compound C1=CC(Cl)=CC=C1CN1CCNCC1 GSJXJZOWHSTWOX-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- KDISMIMTGUMORD-UHFFFAOYSA-N 1-acetylpiperidine Chemical class CC(=O)N1CCCCC1 KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical class C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- NZVZVGPYTICZBZ-UHFFFAOYSA-N 1-benzylpiperidine Chemical compound C=1C=CC=CC=1CN1CCCCC1 NZVZVGPYTICZBZ-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MHGRPEADXUSKAT-UHFFFAOYSA-N 2-(1-benzylpiperidin-4-yl)acetaldehyde Chemical class C1CC(CC=O)CCN1CC1=CC=CC=C1 MHGRPEADXUSKAT-UHFFFAOYSA-N 0.000 description 1
- QRWRJDVVXAXGBT-UHFFFAOYSA-N 2-Methylindoline Chemical compound C1=CC=C2NC(C)CC2=C1 QRWRJDVVXAXGBT-UHFFFAOYSA-N 0.000 description 1
- OTYMUAURNWJXFB-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]acetic acid Chemical compound C1CC(CC(=O)O)CCN1CC1=CC=C(Cl)C=C1 OTYMUAURNWJXFB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- PAEXAIBDCHBNDC-UHFFFAOYSA-N 2-pyridin-4-ylacetic acid Chemical compound OC(=O)CC1=CC=NC=C1 PAEXAIBDCHBNDC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- HOJGUDWNFKNCPF-UHFFFAOYSA-N 3-phenyl-1-piperidin-1-ylpropan-1-one Chemical class C1CCCCN1C(=O)CCC1=CC=CC=C1 HOJGUDWNFKNCPF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- IHSUFLCKRIHFGY-UHFFFAOYSA-N ethyl 2-piperidin-4-ylacetate Chemical compound CCOC(=O)CC1CCNCC1 IHSUFLCKRIHFGY-UHFFFAOYSA-N 0.000 description 1
- QVLJLWHOILVHJJ-UHFFFAOYSA-N ethyl 2-pyridin-4-ylacetate Chemical compound CCOC(=O)CC1=CC=NC=C1 QVLJLWHOILVHJJ-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002483 hydrogen compounds Chemical class 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229950011108 nemonapride Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
本发明公开了式(Ⅰ)化合物或其可药用加成盐,其中:Y代表氧或硫;Z是氮或CH;R1、R2和R3代表氢、卤素、羟基、烷氧基、烷基、三氟甲基或三氟甲氧基;R4和R4 ’代表氢、烷基或与和它们相连的原子一起形成环;R5代表氢、烷基、烷氧基或烷硫基;并且R6代表氢或烷基,或者,R5和R6与它们相连的原子一起形成环;并且R7、R8、R9、R10和R11代表氢或烷基,该化合物可用于治疗和/或预防神经心理疾病,包括神经分裂症、狂噪、痴呆、抑郁症、焦虑、强迫行为、物质滥用、类帕金森氏运动障碍和与使用精神抑制剂有关的运动障碍。本发明还包括式(Ⅶ-a)和(Ⅶ-b)中间体,其中X代表氧或硫或CH2,m为0或1—4的整数,L是离去基团。
Description
发明背景
发明领域
本发明涉及取代的2-(4-苄基-哌嗪-1-基)和2-(1-苄基-哌啶-4-基)乙酮和含有该类化合物的药物组合物。本发明还涉及该类化合物在治疗或预防诸如神经分裂症的精神病及其他中枢神经系统疾病中的用途。
相关技术说明
通称为安定药的常用的精神抑制药的治疗作用通常被认为是通过阻断多巴胺受体而实现的。然而,由于D2受体在脑纹状体区中的阻断,精神抑制药常常会引起不期望的锥体束外副作用(EPS)和迟发性运动障碍。现已识别了多巴胺D4受体亚型(Nature,347:146(Sokoloff等,1990))。其在边缘脑区的独特定位及其对各种精神抑制药的不同识别作用表明:D4受体在神经分裂症的病因学中可以起着重要作用。选择性D4拮抗剂被看作是有效的精神抑制药,而没有常用安定药所显示的神经性副作用。
现已描述了多种4-苄基哌嗪。例如,参见Arch.Med.Res.,25:
435-440(Terron等,1994)和 Toxicol.Appl.Pharmacol.,7:257-267(Schmidt和Martin,1965)。
发明概述
本发明提供了与多巴胺受体亚型相互作用的新型化合物。因此,一般而言,本发明提供了式Ⅰ化合物:其中:
Y代表氧或硫;
Z是氮或CH;
R1、R2和R3各自代表氢、卤素、羟基、低级烷氧基、C1-6烷基、三氟甲基或三氟甲氧基;
R4和R4′各自代表氢或C1-6烷基;或
R4和R4′与连接它们的原子一起形成具有3-7个环原子的环;
R5代表氢、C1-6烷基、C1-6烷氧基或C1-6烷硫基;
R6代表氢或C1-6烷基;或者
R5和R6一起表示C1-5亚烷基、C1-4亚烷氧基、C1-4亚烷硫基,其中的氧或硫原子紧邻苯环,进而与连接它们的原子一起形成具有5-9个环原子的环;和
R7、R8、R9、R10和R11各自代表氢或C1-6烷基。
多巴胺D4受体集中于控制识别和情绪的边缘系统中(Science,265:1034(Taubes,1994))。因此,能与这些受体相互作用的化合物可用于治疗识别障碍。所述识别障碍包括识别缺乏,其是神经分裂症消极症状(社会性退隐和无应答性)的一个重要组成部分。其它障碍包括那些涉及记忆损伤或注意力缺乏等障碍。
本发明化合物在与D4受体亚型的结合中显示了高亲和性和选择性。因此,这些化合物可用于治疗多种神经心理疾病,例如,精神分裂症,精神抑郁症和狂躁症。通过调节D4受体,还可以直接或间接治疗其它多巴胺引起的疾病,如帕金森神经功能障碍和迟发性运动障碍。
由于D4受体选择性存在于控制情绪和识别功能的区域中,通过调节D4受体,本发明化合物还可用于治疗抑郁症、记忆损伤或阿耳茨海默氏病。
因此,在另一方面,本发明提供了一种治疗和/或预防神经心理或情感疾病的方法,所述疾病包括例如神经分裂症、躁狂、痴呆、抑郁、焦虑、强迫行为、(精神作用)物质滥用、记忆损伤、识别缺乏、诸如帕金森神经功能障碍和张力障碍的类帕金森运动障碍以及与使用精神抑制剂有关的运动障碍。本发明的化合物还可用于治疗抑郁症、记忆损伤或阿耳茨海默氏病。此外,本发明化合物可用于治疗其它对多巴胺能阻断有反应的疾病,如(精神作用)物质滥用和强迫观念与行为疾病。本发明的化合物还可用于治疗与使用常用精神抑制剂有关的锥体束外副作用。
另一方面,本发明提供了含有式Ⅰ化合物的药物组合物。
再一方面,本发明提供了制备式Ⅰ化合物的中间体。
发明详述
如上所述,本发明包括式Ⅰ所示的取代的2-(4-苄基)-哌嗪基-和哌啶基-1-乙酮。优选的式Ⅰ化合物是其中R2和R3不同时为氢的化合物。其他优选的式Ⅰ化合物是其中R7、R8、R9和R10均为氢的化合物。在本发明的化合物中,R11优选为氢、甲基或乙基,最优选为氢。
如上所述,本发明包括其中R5和R6一起表示C1-5亚烷基、C1-4亚烷氧基和C1-4亚烷硫基的化合物。在这些化合物中,氧或硫原子紧邻带有R5基的苯环。此时,R5和R6与连接它们的原子一起形成具有5-9个环原子的环。所述环的实例包括下列环:
在上述二环系中,优选其中n为0或整数1或2的化合物。
在这些化合物中,R4和R4′各自代表氢或C1-6烷基;或R4和R4′与连接它们的原子一起形成具有3-7个环原子的环。所得到的代表性螺环系包括下列螺环:其中R5和R6与连接它们的原子一起形成上述具有5-9个环原子的环的化合物由式Ⅱ表示:其中:
X表示氧、硫或CH;
Y是氧或硫;
Z是氮或CH;
n是0或1-4的整数;
R1、R2和R3各自代表氢、卤素、羟基、低级烷氧基、C1-6烷基、三氟甲基或三氟甲氧基;
R4和R4′各自代表氢或C1-6烷基;或
R4和R4′与连接它们的原子一起形成具有3-7个环原子的环;
R7、R8、R9、R10和R11各自代表氢或C1-6烷基。
优选的式Ⅱ化合物是其中R2和R3不同时为氢的化合物。在优选的式Ⅱ化合物中,R4和R4′各自代表氢或C1-4烷基。在其它优选的式Ⅱ化合物中,n是0或1,更优选0。
一组优选的式Ⅱ化合物是其中Y是氧、X是CH2并且Z是CH的化合物。该组化合物由下式Ⅱa表示:其中,n、R1、R2、R3、R4、R4′、R7、R8、R9、R10和R11的定义同上述式Ⅱ中的定义。
在式Ⅱa化合物中,R11优选是氢、甲基或乙基。在优选的式Ⅱa化合物中,R1是氢或卤素,并且R2和R3各自独立选自氢、C1-6烷基和卤素。更优选的式Ⅱa化合物是其中R11是氢或甲基,R1是氢或卤素,并且R2和R3不同时为氢的化合物。尤其优选的式Ⅱa化合物是其中R11是氢或甲基,R2是氢,R3是甲基、甲氧基、氯或氟,R4和R4′各自为氢或低级烷基,最优选C1-2烷基且R1是氢或卤素的化合物。
另一组优选的式Ⅱ化合物是其中Z是氮且X是CH2的化合物。该组化合物通常由下式Ⅱb表示:其中,n、Y、R1、R2、R3、R4、R4′、R7、R8、R9、R10和R11的定义同上述式Ⅱ中的定义。
在上述化合物中,R11优选是氢、甲基或乙基。而且,在这类优选的化合物中,Y是氧,R1是氢或卤素,并且R2和R3各自独立选自氢、C1-6烷基和卤素。更优选的式Ⅱb化合物是其中R11是氢或甲基,Y是氧,R1是氢或卤素,并且R2和R3不同时为氢的化合物。尤其优选的式Ⅱb化合物是其中R11是氢或甲基,Y是氧,R2是氢,R3是甲基、甲氧基、氯或氟,R4和R4′各自为氢或低级烷基,最优选C1-2烷基且R1是氢或卤素的化合物。
其中R5为氢或低级烷基且R6是氢的式Ⅰ化合物由下式Ⅲ表示:其中,Y、Z、R1、R2、R3、R4、R4′、R5、R7、R8、R9、R10和R11的定义同式Ⅰ中的定义。在式Ⅲ化合物中,R2和R3优选不同时为氢。
一组优选的式Ⅲ化合物,下文称为式Ⅲa化合物,是其中Y是氧、Z是氮、R1是氢或卤素,并且R2和R3各自独立选自氢、C1-6烷基和卤素的化合物。更优选的式Ⅲa化合物是其中R2和R3不同时为氢的化合物。其它优选的式Ⅲa化合物是其中R2是氢,R3是甲基、氯或氟,R4和R4′中之一或二者同时为低级烷基,最优选C1-2烷基且R1是氢或卤素的化合物。尤其优选的式Ⅲa化合物是其中R2是氢和R3是在苯环4位上的甲基、氯或氟的化合物。其它尤其优选的式Ⅲa化合物是其中被R2和R3取代的苯基为2-烷氧基-5-卤代苯基的化合物。这类尤其优选化合物的代表性实例是其中带有R2和R3取代基的苯基为2-(C1-C2)烷氧基-5-氟或5-氯苯基的化合物。
另一组优选的式Ⅲ化合物,下文称为式Ⅲb化合物,是其中Y是氧、Z是CH、R1是氢或卤素,并且R2和R3各自独立选自氢、C1-6烷基和卤素的化合物。更优选的式Ⅲb化合物是其中R2和R3不同时为氢的化合物。其它优选的式Ⅲb化合物是其中R2是氢,R3是甲基、氯或氟,R4和R4′中之一或二者同时为低级烷基,最优选C1-2烷基且R1是氢或卤素的化合物。尤其优选的式Ⅲb化合物是其中R2是氢和R3是在苯环4位上的甲基、氯或氟的化合物。其它尤其优选的式Ⅲb化合物是其中被R2和R3取代的苯基为2-烷氧基-5-卤代苯基的化合物。这类尤其优选化合物的代表性实例是其中带有R2和R3取代基的苯基为2-(C1-C2)烷氧基-5-氟或5-氯苯基的化合物。
式Ⅲa和式Ⅲb化合物上的取代基的定义同式Ⅲ化合物中的定义。
另一组优选的本发明化合物由式Ⅳ表示,即,其中R5和R6一起形成环并且R4和R4′也一起构成环:其中,X、n、Y、Z、R1、R2、R3、R7、R8、R9、R10和R11的定义同式Ⅰ中的定义,m是0或1-4的整数。在式Ⅳ化合物中,R2和R3优选不同时为氢。
优选的式Ⅳ化合物是其中X是CH2,n是0,R4和R4′与连接它们的原子一起形成五员碳环(即,m是2)且R11是氢的化合物。当式Ⅳ中的Z是CH时,所得到的m是2的化合物由式Ⅳa表示。当式Ⅳ中的Z是氮时,所得到的m是2的化合物由式Ⅳb表示。
在式Ⅳb和式Ⅳb各自优选的化合物中,X是CH2,Y是氧且n是0。更优选的化合物是其中X是CH2,Y是氧,n是0,R1是氢或卤素,并且R2和R3各自独立选自氢、C1-6烷基和卤素的化合物。还更优选的式IVa和式IVb化合物是其中X是CH2,Y是氧,n是0并且R2和R3不同时为氢的化合物。其它优选的式Ⅳa和式Ⅳb化合物是其中Z是CH,Y是氧,R2是氢且R3是甲基、氟或氯的化合物。特别优选的式Ⅳa和式Ⅳb化合物是其中X是CH2,Y是氧,n是0,R2是氢且R3是苯环4位上的甲基、氟或氯的化合物。其它特别优选的式Ⅳa和式Ⅳb化合物是其中被R2和R3取代的苯基为2-烷氧基-5-卤代苯基的化合物。
本发明还包括用于制备本发明化合物的中间体。因此,本发明提供了下式Ⅶ-a化合物:其中,X、n、Y和R1的定义同式Ⅰ的定义,m是0或1-4的整数,L是离去基团,如卤素、甲磺酰基或甲苯磺酰基。优选的一组Ⅶ-a化合物是其中Y是氧,X是氧或更优选是亚甲基,m是2且R1是氢或卤素的化合物。
优选的一组式Ⅶ-b化合物是其中Y是氧或更优选是亚甲基,且R1是氢或卤素的化合物。其它优选的式Ⅶ-b化合物是其中R4和R4′中之一或二者同时为低级烷基,最优选为C1-2烷基,且R1是氢或卤素的化合物。
在某些情况下,式Ⅰ化合物可以含有一个或多个不对称碳原子,使得化合物可以不同的立体异构体形式存在。这些化合物可以是例如外消旋体或旋光体。在这些情况下,单一的对映体,即,旋光体可通过不对称合成或外消旋体的拆分得到。外消旋体的拆分可通过例如常规方法,例如,在拆分试剂存在下结晶的方法或使用例如手性HPLC柱的色谱法完成。
本发明代表性的化合物,即式Ⅰ所表示的化合物,包括但不局限于表Ⅰ中的化合物及其可药用的酸加成盐。此外,如果本发明化合物是以酸加成盐的形式获得,那么通过酸式盐溶液的碱化可得到游离碱。相反,如果产物为游离碱,则根据由碱性化合物制备酸加成盐的常规方法,通过将游离碱溶解于适当的有机溶剂中,并用酸处理该溶液,就可制得加成盐,特别是可药用的加成盐。
无毒的可药用盐包括酸的盐,所述酸是例如盐酸、磷酸、氢溴酸、硫酸、亚磺酸、甲酸、甲苯磺酸、甲磺酸、硝酸、苯甲酸、柠檬酸、酒石酸、马来酸、氢碘酸、链烷酸,如乙酸、HOOC-(CH2)n-ACOOH,其中n为0-4,等等。本领域熟练技术人员可以识别大量的无毒可药用加成盐。
本发明还包括式Ⅰ化合物的酰化前体药物。本领域熟练技术人员知道各种合成方法,这些方法可用于制备无毒的可药用加成盐和式Ⅰ所包括化合物的酰化前体药物。
本发明中的“烷基”或“低级烷基”是指C1-6烷基,即具有1-6个碳原子的直链或支链烷基,例如,甲基、乙基、丙基、异丙基、正丁基、仲丁基、叔丁基、戊基、2-戊基、异戊基、新戊基、己基、2-己基、3-己基和3-甲基戊基。
本发明中的“烷氧基”或“低级烷氧基”是指C1-C6烷氧基,即具有1-6个碳原子的直链或支链烷氧基,例如,甲氧基、乙氧基、丙氧基、异丙氧基、正丁氧基、仲丁氧基、叔丁氧基、戊氧基、2-戊氧基、异戊氧基、新戊氧基、己氧基、2-己氧基、3-己氧基和3-甲基戊氧基。
本发明中的术语“卤素”是指氟、溴、氯和碘。
本发明的代表性化合物列于下表1中。
本发明化合物可用于治疗神经心理疾病;本发明化合物的药物用途可通过下文实施例中所描述的多巴胺受体亚型亲合性试验来说明。本发明的取代的2-(4-苯基甲基)-哌嗪基-1-乙酮与多巴胺受体亚型的相互作用产生了这些化合物的药物活性。
通式Ⅰ化合物可采用含有常用的无毒可药用载体、辅药和赋形剂的剂量单位制剂的形式,通过吸入或喷雾或经直肠实施口服给药、局部给药、肠胃外给药。此处使用的术语“肠胃外给药”包括皮下注射、静脉内、肌内或胸骨内注射或输注技术。此外,本发明还提供了含有通式Ⅰ化合物和可药用载体的药物制剂。一种或多种通式Ⅰ化合物可结合一种或多种无毒可药用载体和/或稀释剂和/或辅药和其它活性组分-如果需要的话。含有通式Ⅰ化合物的药物组合物可以适用于口服的剂型存在,例如,片剂、锭剂、糖锭、含水或油状悬浮液、可分散粉末或颗粒、乳液、硬或软胶囊,或糖浆或酏剂。
用于口服的组合物可根据现有技术中任何已知的用于生产药物组合物的方法来制备。这类组合物可含有一种或多种选自甜味剂、增香剂、着色剂和防腐剂的试剂,以提供药物上美观且适口的药物制剂。片剂中含有与适用于生产片剂的无毒可药用赋形剂相混合的活性组分。这类赋形剂可以是例如:惰性稀释剂,如碳酸钙、碳酸钠、乳糖、磷酸钙或磷酸钠;成粒剂和崩解剂,如玉米淀粉或藻酸;粘合剂,如淀粉、明胶或阿拉伯胶;以及润滑剂,如硬脂酸镁,硬脂酸或滑石。片剂可以是未涂覆的,或者,可以按已知技术进行涂覆以延缓在胃肠道中的崩解与吸收,从而实现在较长时间内的持续作用。例如,可使用延迟物质,如甘油单硬脂酸酯或甘油二硬脂酸酯。
口服制剂也可以硬胶囊形式存在,其中活性组分与诸如碳酸钙、磷酸钙或高岭土的惰性固体稀释剂混合;或以软胶囊形式存在,其中活性组分与水或诸如花生油、液体石蜡或橄榄油的油性介质混合。
含水悬浮液中含有与适于生产含水悬浮液的赋形剂相混的活性物质。此类赋形剂是悬浮剂,如羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、藻酸钠、聚乙烯吡咯烷酮,黄芪胶和阿拉伯胶;分散剂或湿润剂可以是天然磷脂,如卵磷脂;或烯化氧与脂肪酸的缩合产物,如聚氧乙烯硬脂酸酯;或环氧乙烷与长链脂肪醇的缩合产物,如十七乙氧基十六醇;或环氧乙烷与衍生自脂肪酸和己糖醇的偏酯的缩合产物,如聚氧乙烯山梨糖醇单油酸酯;或环氧乙烷与衍生自脂肪酸和己糖醇酐的偏酯的缩合产物,如聚氧乙烯山梨糖醇单油酸酯。含水悬浮液中还可含有一种或多种防腐剂,如对羟基苯甲酸乙酯或正丙酯,一种或多种着色剂,一种或多种甜味剂,以及一种或多种甜味剂,如蔗糖或糖精。
油性悬浮液可通过将活性组分悬浮在植物油或矿物油中而配制,其中植物油是例如花生油、橄榄油、芝麻油或椰子油,矿物油是例如液体石蜡。这类油性悬浮液可含有增稠剂,如蜂蜡、硬石蜡或鲸蜡醇。可加入如上所述的甜味剂和增香剂以获得可口的口服制品。这些组合物可通过加入诸如抗坏血酸的抗氧化剂来保存。
适于通过加水制备含水悬浮液的分散粉末和颗粒可得到与分散剂或润湿剂、悬浮剂和一种或多种防腐剂相混的活性组分。合适的分散剂或润湿剂及悬浮剂如上所述。也可存在其它的赋形剂,如甜味剂、增香剂和着色剂。
本发明的药物组合物还可以水包油型乳液的形式存在。油相可为诸如橄榄油或花生油的植物油或诸如液体石蜡的矿物油或者这些油的混合油。合适的乳化剂可为天然树胶,例如阿拉伯树胶或黄芪胶;天然磷脂,例如大豆磷脂、卵磷脂;和衍生自脂肪酸和己糖醇、酸酐的酯或偏酯,例如脱水山梨糖醇一油酸酯;以及所述偏酯与环氧乙烷的缩合产物,例如聚氧乙烯脱水山梨糖醇一油酸酯。乳液中还可含有甜味剂和增香剂。
糖浆和酏剂可用诸如甘油、丙二醇、山梨醇或蔗糖的甜味剂配制。这类制剂中还可含有湿润剂、防腐剂以及增香剂和着色剂。药物组合物可为无菌注射含水或含油悬浮液。该悬浮液可根据现有技术,采用上述合适的分散剂或润湿剂以及悬浮剂来配制。无菌注射制剂也可是无菌注射溶液或是无毒的肠胃外可接受稀释剂或溶剂中的悬浮液,例如是1,3-丁二醇溶液。能用的可接受的赋形剂和溶剂是水、林格液和等渗氯化钠溶液。此外,无菌、固定油常用作溶剂或悬浮介质。为此,可使用任何温和的固定油,包括合成的一或二甘油酯。此外,在注射制剂的制备中,发现了诸如油酸的脂肪酸的用途。
通式Ⅰ化合物也可以栓剂的剂型用于药物的直肠给药。这些组合物可通过将所述药物与适当的无刺激赋形剂混合来制备,其中无刺激赋形剂在常温下为固态,但在直肠温度下为液态,因而在直肠中融化释放药物。这种赋形剂可为可可油和聚乙二醇。
通式Ⅰ化合物可在无菌介质中肠胃外给药。根据所用的介质和浓度的不同,药物既可悬浮在介质中,也可溶解在介质中。将诸如局部麻醉剂的辅药、防腐剂和缓冲剂溶解在介质中是有利的。
在上述疾病的治疗中,可采用的剂量为每天每千克体重约0.1毫克~140毫克(每天每位患者约0.5毫克~7克)。可与载体物料结合形成单剂量形式的活性组分的量取决于接受治疗的患者以及具体的给药方式。单位剂量通常含有约1毫克~500毫克活性组分。
但是,可以理解的是,对于任何特定病人的具体剂量范围将取决于很多因素,包括所用具体化合物的活性、患者年龄、体重、一般健康状况、性别、饮食、给药时间、给药途径和排泄速率,药物组合情况以及进行治疗的具体疾病的严重程度。
下列反应图解说明了适用于制备本发明化合物的代表性方法。本领域技术熟练人员将认识到可以通过改变原料以及采用附加的步骤来制备本发明包括的化合物。例如,在某些情况下,需要对诸如氨基基团的活性部位进行保护。
根据反应图解1所示反应可制得式Ⅰ的2-(4-苄基-哌嗪-1-基)-1-乙酮化合物。
反应图解1其中,R1、R2、R3、R4、R4′、R5、R6和Y的定义同上文所述式Ⅰ中的定义。
如反应图解1所示,通式Ⅴ表示的具有适当仲氨基的苯胺与氯代乙酰氯或其适当的衍生物(Ⅵ)缩合。然后,使得到的中间体Ⅶ与通式Ⅷ表示的哌嗪衍生物反应,得到式Ⅰ表示的2-(4-苄基-哌嗪-1-基)-1-乙酮衍生物。所述哌嗪衍生物Ⅷ一般可由市场上购得,但也可以采用文献中公开的方法制备。
根据下面反应图解2所示的反应可制得本发明的2-(4-苄基-哌嗪-1-基)-1-乙酮类化合物。
如反应图解2所示,在诸如铂的催化剂存在下,使用氢气可以将吡啶-4-乙酸的酯(Ⅺ)还原,得到哌啶氨基酯衍生物Ⅻ。氨基酯Ⅻ可以与含有离去基团W的适当的苄烷基化试剂缩合,其中,W可以是卤素或磺酸酯等,得到结构式Ⅷ所示的N-苄基哌啶。Ⅷ的酯基可以在碱中皂化,得到结构式ⅩⅣ所示的氨基酸,该氨基酸随后与仲胺缩合,得到所需的式Ⅰ化合物,其中Z是次甲基碳(Z=CH)。
本领域熟练技术人员可认识到的是,如下列实施例所述,可以改变原料和采用附加的步骤来制得本发明所包括的化合物。在某些情况下,为了实现上文所述的某些转变,对一些活性官能团的保护是必要的。通常,对于有机合成领域的熟练技术人员而言,对于这些保护基团的需求以及接上并除去这些基团的条件是显而易见的。
本发明将通过下列实施例进一步阐述,并不认为这些实施例将本发明的范围或精神限制在其所述的具体步骤范围内。
实施例1
原料和中间体的制备
原料和各种中间体可以市场上获得或由市购的有机化合物制得或采用公知的合成方法制得。
制备本发明乙酮中间体的方法的代表性实施例如下所述。
2-氯-1-二氢吲哚基乙-1-酮
将一定量的2,3-二氢-1H-1-吲哚(也称作二氢吲哚,2.1g,17.6mmol)溶解在甲苯(60ml)中。向该胺的甲苯溶液中加入溶解在1,2-二氯乙烷(20ml)中的乙酰氯(2.0g,17.6mmol)。一经加入酰基氯,反应混合物即变为棕色。在搅拌条件下,于室温下进行反应约3小时,之后,用乙酸乙酯稀释反应混合物并用50∶50(v/v)的水∶饱和NaCl溶液洗涤(2次)。用无水MgSO4干燥有机层并浓缩,得到浅棕色固体状的2-氯-1-(2,3-二氢-1H-1-吲哚基)-1-乙酮(也可以称为2-氯-1-二氢吲哚基乙-1-酮),收率85%(2.92g,15mmol)。
实施例2
向(4-氯苄基)-哌嗪(1.5g,7.2mmol)的乙腈(100ml)溶液中加入2-氯-1-(2,3-二氢-1H-1-吲哚基)-1-乙酮(1.4g,7.16mmol)和K2CO3(12g,87mmol)。反应混合物在室温下反应约6小时。然后过滤反应混合物并浓缩,残余物再悬浮在乙酸乙酯中并用HCl(3M)萃取。水相用NaOH(10M)碱化,然后用另外的乙酸乙酯反萃取。最终的乙酸乙酯相用盐水洗涤、用无水MgSO4干燥并浓缩。得到浅粉色固体状的2-(4-(4-氯苄基)-哌嗪基-1-(2,3-二氢-1H-1-吲哚基)-1-乙酮(或称为:2-(4-氯苄基)哌嗪基)-1-二氢吲哚基乙-1-酮)(1.3g,3.5mmol),收率50%。
Mp:139.5-140℃。1H NMR(400MHz,CDCl3)d8.23ppm(d.,1H,8.8Hz),7.26ppm(m.,4H),7.24ppm(m.,2H),7.01ppm(t.,1H,7.2Hz),4.16ppm(t.,2H,8.4Hz),3.48ppm(s,2H),3.25ppm(s.,2H),3.19ppm(br.t.,2H,8.4Hz),2.64ppm(br,s,4H),2.51ppm(br.s.,4H)和MS(CI)M+369。
由甲醇溶液(使用48%HBr水溶液)制得标题化合物的HBr盐(化合物19),从乙醇/丙酮中重结晶,得到白色固体,mp:258-260℃。
实施例3
基本上按照上述实施例1和2的方法制备下述化合物:
(a)2-(4-(4-氯苄基)-哌嗪基-1-(2-甲基-2,3-二氢-1H-1-吲哚基)-1-乙酮(化合物3)(二氢溴酸盐:化合物3a)。
(b)2-(4-(4-氯苄基)-哌嗪基-1-(1,2,3,4-四氢-1-喹啉基)-1-乙酮(化合物4)(二氢溴酸盐:化合物4a)。
(c)2-(4-(4-氯苄基)-哌嗪基-1-(3,4-二氢-2H-苯并[b]1,4-恶嗪-4-基)-1-乙酮(化合物5)(二氢溴酸盐:化合物5a)。
(d)2-(4-(4-氯苄基)-哌嗪基-1-(3,4-二氢-2H-苯并[b]1,4-噻嗪-4-基)-1-乙酮(化合物6)(二氢溴酸盐:化合物6a)。
(e)1-(2,2-二甲基二氢吲哚基)-2-(4-(4-氯苄基)-哌嗪基)乙-1-酮(化合物7)。
(f)1-(2,2-二甲基二氢吲哚基)-2-(4-(4-甲基苄基)-哌嗪基)乙-1-酮(化合物8)。
(g)1-(2-甲基二氢吲哚基)-2-(4-(4-甲基苄基)-哌嗪基)乙-1-酮(化合物9)。
(h)2-(4-[4-氯苄基]-哌嗪基)-1-螺[环戊烷-2,2′-二氢吲哚-1-基]乙酮(化合物10)。
(i)2-(4-(4-氯苄基)-哌嗪基)-1-(4-氟二氢吲哚基)乙-1-酮(化合物11)。
(j)1-(5-氯-2,2-二甲基二氢吲哚基)-2-(4-(4-氯苄基)哌嗪基)乙-1-酮(化合物12)。
(k)2-(4-(5-氯-2-甲氧基苄基)哌嗪基)-1-(2-甲基二氢吲哚基)乙-1-酮(化合物13)。
(m)1-二氢吲哚基-2-(4-(4-甲基苄基)哌嗪基)丙-1-酮(化合物15)。
(n)1-(2,2-二甲基二氢吲哚基)-2-(4-(4-氟苄基)哌嗪基)乙-1-酮(化合物16)。
(o)2-(4-(4-氯苄基)哌嗪基)-1-(7-甲基二氢吲哚基)乙-1-酮(化合物17)。
(p)1-(6-氯二氢吲哚基)-2-(4-(4-氯苄基)哌嗪基)乙-1-酮(化合物18)。
(q)N-丁基-2-(4-(4-氯苄基)哌嗪基)-N-苯基乙酰胺(化合物2)(二氢溴酸盐:化合物2a)。
实施例4
将4-吡啶基乙酸乙酯(5g)溶解在乙醇(30ml)中,用氧化铂催化剂(30mg)处理并在帕尔装置上加氢4小时。虑除催化剂,在真空条件下除去溶剂以分离出4-哌啶基乙酸乙酯。然后将其溶解在乙腈(50ml)中,并用4-氯苄基氯(4.9g)和碳酸钠(10g)处理。在甲醇(30ml)中加热得到的混合物并用氢氧化锂(2g)的水(10ml)溶液处理。将混合物静置过夜。加入47.6ml 1N的HCl,然后浓缩并用氯仿萃取残余物,得到所需的1-(4-氯苄基)-4-哌啶乙酸。将一部分产物(1g)溶解在二氯甲烷中,用1,1′-羰基二咪唑(0.65g)处理,并静置过夜。然后将得到的溶液用2-甲基二氢吲哚(0.5g)处理。2小时后,将得到的混合物用水洗涤3次,干燥并浓缩。用硅胶柱色谱法提纯,得到1.2g所需的2-(1-[4-氯苄基]哌嗪-4-基)-1-(2-甲基二氢吲哚-1-基)-1-乙酮(化合物1)。随后制得二盐酸盐(化合物1a)。
实施例5
D2和D4受体结合活性试验
本发明化合物的药学实用性通过下述多巴胺受体亚型亲合性试验来说明。
将含有由c-DNA克隆的人类D2或D4受体的CHO细胞片用于试验(Tallman,J.f.等人,J.Pharm.Exp.Ther.,1997,282,1011)。在温度为4℃、pH为7.4且含有120mM NaCl、1mM EDTA和5mM MgCl2的100体积(重量/体积)0.05M Tris-HCl缓冲液中匀化该克隆膜。将样品在48,000Xg下离心,然后再次进行悬浮与匀化。将最终的组织样品冷冻直至使用。在使用前,将组织按1∶20(重量/体积)的比例重新悬浮在含120mM NaCl的0.05MTris-HCl缓冲液中。
在48℃下进行培养,且1毫升总培养物中含有0.4毫升组织样品、0.5nM 3H-YM 09151-2(Nemonapride,顺-5-氯-2-甲氧基-4-(甲基氨基)-N-(2-甲基-2-(苯基甲基)-3-吡咯烷基)苯甲酰胺)以及试验的化合物。非特异性结合定义为在1mM螺哌隆存在下发现的结合;无其它加成时,非特异性结合少于总结合的20%。对于大鼠的纹状体匀浆,诸如式Ⅰ包括的化合物对D2和D4受体亚型的结合特性如表2所示。
表2化合物序号1 D4K1(nM) D2K1(nM)1 7 922 154 ND3 0.7 744 47 10,0005 429 26106 14.2 10,000
1化合物序号对应于表1所示化合物。
式Ⅰ化合物对D4受体的结合常数以nM表示,通常在大约0.1纳摩尔(nM)~500纳摩尔(nM)之间。优选的化合物具有大约0.1-100nM的结合常数。优选的化合物对D2受体的结合常数通常是其对D4受体的结合常数的至少大约10-15倍。因此,本发明化合物对D4受体的选择性是其对D2受体的选择性的至少大约10倍。优选这些化合物对D4受体的选择性是其对D2受体的选择性的至少20倍,更优选至少25~50倍,最优选式Ⅰ化合物对D4受体的选择性是对D2受体的选择性的至少100倍。
在上文中,本发明化合物及其制备和使用的方式和方法以完整、清楚、简洁和准确的术语进行了描述,使得与之相关的本领域技术熟练人员能制备与使用本发明的化合物。可以理解的是:上文描述的是本发明的优选实施方案,并且,在不偏离权利要求所述的本发明的精神和范围的条件下可进行改进。为了特别指出和清晰地要求保护本发明的主题,下列权利要求总结了本发明。
Claims (38)
1.下式所示的化合物或其可药用的加成盐:其中:
Y代表氧或硫;
Z是氮或CH;
R1、R2和R3各自代表氢、卤素、羟基、C1-6烷氧基、C1-6烷基、三氟甲基或三氟甲氧基;
R4和R4′各自代表氢或C1-6烷基;或
R4和R4′与连接它们的原子一起形成具有3-7个环原子的环;
R5代表氢、C1-6烷基、C1-6烷氧基或C1-6烷硫基;
R6代表氢或C1-6烷基;或者
R5和R6一起代表C1-5亚烷基、C1-5亚烷氧基、C1-5亚烷硫基,其中的氧或硫原子紧邻苯环,进而与连接它们的原子一起形成具有5-9个环原子的环;和
R7、R8、R9、R10和R11各自代表氢或C1-6烷基。
2.根据权利要求1的化合物,其中R2和R3中仅一个为氢。
7.根据权利要求1的化合物,其具有下式结构:其中,X、n、R1、R2、R3、R7、R8、R9、R10和R11的定义同权利要求1中的定义。
8.根据权利要求7的化合物,其中Y是氧、R1是氢或卤素,并且R2和R3各自独立地选自氢、C1-6烷基和卤素。
9.根据权利要求8的化合物,其中R2和R3不同时为氢。
10.根据权利要求8的化合物,其中R2为氢和R3为甲基、氯或氟。
11.根据权利要求10的化合物,其中R3是在苯环的4位上的甲基、氯或氟。
12.根据权利要求11的化合物,其中n是0。
13.根据权利要求6的化合物,其中Y是氧、R1是氢或卤素,并且R2和R3各自独立地选自氢、C1-6烷基和卤素。
14.根据权利要求1的化合物,其为2-(4-(4-氯苄基)哌嗪基)-1-二氢吲哚基乙-1-酮。
15.根据权利要求1的化合物,其为2-(4-(4-氯苄基)哌嗪基-1-(2-甲基-2,3-二氢-1H-1-吲哚基)-1-乙酮。
16.根据权利要求1的化合物,其为2-(4-(4-氯苄基)哌嗪基-1-(1,2,3,4-四氢-1-喹啉基)-1-乙酮。
17.根据权利要求1的化合物,其为2-(4-(4-氯苄基)哌嗪基-1-(3,4-二氢-2H-苯并[b]1,4-恶嗪-4-基)-1-乙酮。
18.根据权利要求1的化合物,其为2-(4-(4-氯苄基)-哌嗪基-1-(3,4-二氢-2H-苯并[b]1,4-噻嗪-4-基)-1-乙酮。
19.根据权利要求1的化合物,其为1-(2,2-二甲基二氢吲哚基)-2-(4-(4-氯苄基)哌嗪基)乙-1-酮。
20.根据权利要求1的化合物,其为1-(2,2-二甲基二氢吲哚基)-2-(4-(4-甲基苄基)哌嗪基)乙-1-酮。
21.根据权利要求1的化合物,其为1-(2-甲基二氢吲哚基)-2-(4-(4-甲基苄基)哌嗪基)乙-1-酮。
22.根据权利要求1的化合物,其为2-(4-(4-氯苄基)哌嗪基)-1-螺[环戊烷-2,2′-二氢吲哚-1-基]乙酮。
23.根据权利要求1的化合物,其为2-(4-(4-氯苄基)哌嗪基)-1-(4-氟二氢吲哚基)乙-1-酮。
24.根据权利要求1的化合物,其为1-(5-氯-2,2-二甲基二氢吲哚基)-2-(4-(4-氯苄基)哌嗪基)乙-1-酮。
25.根据权利要求1的化合物,其为2-(4-(5-氯-2-甲氧基苄基)哌嗪基)-1-(2-甲基二氢吲哚基)乙-1-酮。
27.根据权利要求1的化合物,其为
28.根据权利要求1的化合物,其为1-二氢吲哚基-2-(4-(4-甲基苄基)哌嗪基)丙-1-酮。
29.根据权利要求1的化合物,其为1-(2,2-二甲基二氢吲哚基)-2-(4-(4-氟苄基)哌嗪基)乙-1-酮。
30.根据权利要求1的化合物,其为2-(4-(4-氯苄基)哌嗪基)-1-(7-甲基二氢吲哚基)乙-1-酮。
31.根据权利要求1的化合物,其为1-(6-氯二氢吲哚基)-2-(4-(4-氯苄基)哌嗪基)乙-1-酮。
32.根据权利要求1的化合物,其为1-(4-(4-氟苄基)-哌嗪基)-2-二氢吲哚基乙-1-酮。
33.根据权利要求1的化合物,其为N-丁基-2-(4-(4-氯苄基)哌嗪基)-N-苯基乙酰胺。
35.根据权利要求34的化合物,其中Y是氧、X是亚甲基、m是2且R1是氢或卤素。
37.根据权利要求36的化合物,其中Y是氧或亚甲基,R5是氢或C1-6烷基,且R1是氢或卤素。
38.根据权利要求37的化合物,其中R4和R4′中之一或二者为C1-2烷基且R1是卤素。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3098798A | 1998-02-26 | 1998-02-26 | |
US09/030,987 | 1998-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1293669A true CN1293669A (zh) | 2001-05-02 |
Family
ID=21857045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99804026A Pending CN1293669A (zh) | 1998-02-26 | 1999-02-26 | 苄基哌嗪基-和苄基哌啶基-乙酮衍生物、其制备方法及其用作多巴胺d 受体拮抗剂的用途 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1068193A1 (zh) |
JP (1) | JP2002504549A (zh) |
KR (1) | KR20010041341A (zh) |
CN (1) | CN1293669A (zh) |
AU (1) | AU2881499A (zh) |
CA (1) | CA2321830A1 (zh) |
HU (1) | HUP0100926A3 (zh) |
IL (1) | IL137930A0 (zh) |
NO (1) | NO20004271L (zh) |
PL (1) | PL342597A1 (zh) |
WO (1) | WO1999043670A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003095437A1 (fr) * | 2002-05-08 | 2003-11-20 | Shanghai Institute Of Pharmaceutical Industry | Derives d'aralkyl formyl-alkyl piperazine et leurs utilisations en tant qu'agent protecteur du nerf cerebral |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
AU5487300A (en) * | 1999-06-14 | 2001-01-02 | Neurogen Corporation | Benzylpiperazinyl-indolinylethanones |
US6355644B1 (en) | 1999-06-14 | 2002-03-12 | Neurogen Corporation | Benzylpiperazinyl-indolinylethanones |
EP1177792A3 (en) | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
KR100394086B1 (ko) | 2000-12-04 | 2003-08-06 | 한국과학기술연구원 | 도파민 d3 및 d4 수용체의 선택적 활성을 지닌 신규이소옥사졸릴알킬피페라진 유도체와, 이의 제조방법 |
KR100394083B1 (ko) | 2000-12-04 | 2003-08-06 | 학교법인 성신학원 | 도파민 d3 및 d4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법 |
DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
LT3071203T (lt) | 2013-11-18 | 2021-05-25 | Forma Therapeutics, Inc. | Tetrahidrochinolino kompozicijos kaip bet bromodomeno inhibitoriai |
EP3071205B1 (en) | 2013-11-18 | 2020-02-05 | Forma Therapeutics, Inc. | Benzopiperazine compositions as bet bromodomain inhibitors |
SG11201604795RA (en) | 2013-12-20 | 2016-07-28 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
CN103966340B (zh) * | 2014-05-26 | 2015-09-16 | 宁波大学 | 一种用于辅助诊断阿尔茨海默病的检测试剂盒及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2863752A (en) * | 1953-10-30 | 1958-12-09 | Monsanto Chemicals | Herbicides |
US2909523A (en) * | 1957-10-11 | 1959-10-20 | American Cyanamid Co | Substituted piperazines and method of preparing the same |
US3268584A (en) * | 1961-08-28 | 1966-08-23 | Monsanto Co | Herbicidal alpha-haloacetanilides |
GB1065801A (en) * | 1964-02-19 | 1967-04-19 | Nippon Soda Co | N-substituted fluoroacetamides and their use as insecticides |
DE2604224A1 (de) * | 1976-02-04 | 1977-08-11 | Hoechst Ag | Herbizide mittel |
JPS5318540A (en) * | 1976-08-02 | 1978-02-20 | Nippon Nohyaku Co Ltd | Alpha-chloroacetamides and their use |
WO1989008654A1 (en) * | 1988-03-11 | 1989-09-21 | Pfizer Inc. | Pyrroloquinoline and pyrrolophenothiazine carboxamides and related compounds |
WO1998007703A1 (fr) * | 1996-08-22 | 1998-02-26 | Meiji Seika Kaisha, Ltd. | Derives quinoleine et agent psychotrope |
EP0920423B1 (en) * | 1996-08-23 | 2005-01-26 | Neurosearch A/S | Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine d4 receptor antagonists |
AU6256198A (en) * | 1997-02-19 | 1998-09-09 | Hoechst Marion Roussel, Inc. | Benzamides having dopamine d4 receptor affinity |
WO1999021848A2 (en) * | 1997-10-27 | 1999-05-06 | Neurogen Corporation | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
AU1286399A (en) * | 1997-10-31 | 1999-05-24 | Neurogen Corporation | 3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands |
-
1999
- 1999-02-26 CN CN99804026A patent/CN1293669A/zh active Pending
- 1999-02-26 WO PCT/US1999/004309 patent/WO1999043670A1/en not_active Application Discontinuation
- 1999-02-26 PL PL99342597A patent/PL342597A1/xx not_active Application Discontinuation
- 1999-02-26 IL IL13793099A patent/IL137930A0/xx unknown
- 1999-02-26 EP EP99909657A patent/EP1068193A1/en not_active Withdrawn
- 1999-02-26 KR KR1020007009454A patent/KR20010041341A/ko not_active Application Discontinuation
- 1999-02-26 HU HU0100926A patent/HUP0100926A3/hu unknown
- 1999-02-26 CA CA002321830A patent/CA2321830A1/en not_active Abandoned
- 1999-02-26 AU AU28814/99A patent/AU2881499A/en not_active Abandoned
- 1999-02-26 JP JP2000533426A patent/JP2002504549A/ja active Pending
-
2000
- 2000-08-25 NO NO20004271A patent/NO20004271L/no not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003095437A1 (fr) * | 2002-05-08 | 2003-11-20 | Shanghai Institute Of Pharmaceutical Industry | Derives d'aralkyl formyl-alkyl piperazine et leurs utilisations en tant qu'agent protecteur du nerf cerebral |
US7326710B2 (en) | 2002-05-08 | 2008-02-05 | Shanghai Institute Of Pharmaceutical Industry | Aralkyl formyl-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent |
Also Published As
Publication number | Publication date |
---|---|
NO20004271D0 (no) | 2000-08-25 |
JP2002504549A (ja) | 2002-02-12 |
IL137930A0 (en) | 2001-10-31 |
HUP0100926A2 (hu) | 2001-09-28 |
HUP0100926A3 (en) | 2003-03-28 |
WO1999043670A1 (en) | 1999-09-02 |
KR20010041341A (ko) | 2001-05-15 |
EP1068193A1 (en) | 2001-01-17 |
NO20004271L (no) | 2000-10-25 |
PL342597A1 (en) | 2001-06-18 |
AU2881499A (en) | 1999-09-15 |
CA2321830A1 (en) | 1999-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6444819B1 (en) | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands | |
CN1227237C (zh) | 作为五羟色胺5-ht2受体拮抗剂的哌嗪基吡嗪化合物 | |
CN1293669A (zh) | 苄基哌嗪基-和苄基哌啶基-乙酮衍生物、其制备方法及其用作多巴胺d 受体拮抗剂的用途 | |
JP4150161B2 (ja) | 置換されたクロマン誘導体 | |
CN1662534A (zh) | 用作抗精神病和抗肥胖药物的1,2,3,4,7,8-六氢-6h-[1,4]二氮杂庚因并[6,7,1-ij]喹啉衍生物 | |
US6214829B1 (en) | Piperazine compounds, their preparation, and methods of using them | |
CN1185214C (zh) | 新的茚并吲哚酮化合物,其制备方法和含有这种化合物的药物组合物 | |
CN1167694C (zh) | 1-苯基-4-(1-[2-芳基]环丙基)甲基哌嗪:多巴胺受体配体 | |
CN1188405C (zh) | 新的吗啉代苯甲酰胺盐 | |
CA2307905A1 (en) | 3-aminoalkylamino-2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands | |
CN1043764C (zh) | 作为5-ht1a拮抗剂的双环甲酰胺 | |
CN1148594A (zh) | 哌啶基甲基噁唑烷酮 | |
US6100255A (en) | 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands | |
CN1439004A (zh) | 用于治疗中枢神经系统疾病的吲哚衍生物 | |
CN1361776A (zh) | 新的氟化咪唑啉苯并二噁烷,其制备及其治疗用途 | |
US6291463B1 (en) | 1-(Benzothiazol-2-yl)-4-(1-phenylmethyl) piperazines: dopamine receptor subtype specific ligands | |
US6486164B2 (en) | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | |
MXPA00008291A (en) | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 | |
WO1999064396A1 (en) | Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands | |
CN1022485C (zh) | 制备芳族2-氨烷基-1,2-苯并异噻唑-3(2h)酮-1,1-二氧化物衍生物的方法 | |
WO2000012500A2 (en) | 2-aryl-4-(1-[4-heteroaryl]piperazin-1-yl) methylimidazoles: dopamine d4 receptor subtype ligands | |
WO2000000482A1 (en) | 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines: dopamine receptor subtype specific ligands | |
CA2336089A1 (en) | 6-(4-arylalkylpiperazin-1-yl)benzodioxane and 6-(4-arylalkylpiperazin-1-yl)chromane derivatives: dopamine receptor subtype specific ligands | |
CZ2000275A3 (cs) | Substituované 1,2,2,4-tetrahydronaftalenové deriváty |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1034710 Country of ref document: HK |